Drug Trial Radar · NCT03199989
Efficacy of Postoperative Adjuvant Chemotherapy for Stage II Colon Cancer With High Risk Factors(EPAC1)
Last checked: Nov 19, 2026Latest source record: Mar 6, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
1,254
Planned (sponsor's estimate)
Start
Jun 1, 2017
Primary completion
Jul 31, 2021
Study completion Jul 31, 2024
Sponsor
- Lead sponsor
- Peking University Cancer Hospital & InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Peking Union Medical College Hospital; Peking University People's Hospital
- First posted
- Jun 27, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to design a prospective randomized clinical trial to explore whether postoperative adjuvant chemotherapy may provide survival benefit for stage II colon cancer patients with high risk factors.Therefore the investigators can provide high level clinical evidence of indications for patients with colon cancer with stage II colon cancer.
Conditions
- Adjuvant Chemotherapy
Interventions
CapeOX(Capecitabine+Oxaliplatin)Drug
Patients enrolled in the chemotherapy group would receive postoperative chemotherapy CapeOX(Capecitabine+Oxaliplatin)for 6 months
ObservationOther
Patients enrolled in the observation group would not receive any chemotherapy drugs just for observation
Primary outcomes
What the sponsor says the trial is designed to measure.
- 3-year disease free survivalTime frame: At least 3 years after the last patient enrolled
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing cancer hospital
Beijing, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.